Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Protagonist Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $131.20M, up 231.8% year over year. For fiscal 2025 it was $57.67M, down 68.7% from the year before. The highest annual figure on record is $184.15M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.67M | -68.7% |
| FY2024 | Dec 31, 2024 | $184.15M | – |
| FY2023 | Dec 31, 2023 | -$70.24M | – |
| FY2022 | Dec 31, 2022 | -$108.14M | – |
| FY2021 | Dec 31, 2021 | -$107.87M | – |
| FY2020 | Dec 31, 2020 | -$72.48M | – |
| FY2019 | Dec 31, 2019 | -$41.53M | – |
| FY2018 | Dec 31, 2018 | -$49.95M | -1390.0% |
| FY2017 | Dec 31, 2017 | $3.87M | – |
| FY2016 | Dec 31, 2016 | -$29.97M | – |
| FY2015 | Dec 31, 2015 | -$14.39M | – |
| FY2014 | Dec 31, 2014 | -$7.74M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $219.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$48.94M | -139.0% |
| Q4 FY2025 | Dec 31, 2025 | -$36.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.78M | -110.7% |
| Q1 FY2025 | Mar 31, 2025 | $125.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.18M | -272.0% |
| Q3 FY2024 | Sep 30, 2024 | -$27.86M | – |
| Q2 FY2024 | Jun 30, 2024 | $268.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$27.43M | – |
| Q4 FY2023 | Dec 31, 2023 | $16.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.24M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.67M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.94M | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.29M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.48M | -685.3% |
| Q1 FY2020 | Mar 31, 2020 | -$15.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.29M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.25M | – |
| Q2 FY2019 | Jun 30, 2019 | $3.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.14M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.28M | -122.8% |
| Q2 FY2018 | Jun 30, 2018 | -$15.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.14M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.15M | – |
| Q3 FY2017 | Sep 30, 2017 | $40.70M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.33M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.36M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.68M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.98M | – |
See a number that looks wrong?